AHIP chief executive to step down in October
Matt Eyles will depart his post after a nearly five-year tenure with AHIP. The organization is launching a nationwide search for his replacement.
Cleveland Clinic outpaced expense growth to return to profitability in Q1
The health system noted that growing expenses are still a concern, with labor costs like overtime increasing.
US projected to hit record-low uninsurance rate this year, before rates tick upward
As federal aid expires, lower-income Americans — who saw the largest recent gains in uninsurance trends — will likely be affected the most, according to experts.
Health tech startup Florence buys Zipnosis from Bright Health
Bright Health, which recently said it’s looking to exit the insurance business, purchased telehealth company Zipnosis in 2021.
Biden administration aims to increase Medicaid drug transparency
The notice of proposed rulemaking recommends that the CMS and states get a drug price verification survey tool to verify prices and negotiate for expensive drugs under Medicaid.
House lawmakers, PBM lobby spar over committee hearing
At the latest congressional inquiry into pharmacy benefit managers, lawmakers argued the middlemen profit at the expense of patients and taxpayers.
Digital health funding holds steady in Q1 after year of decline
The sector defied trends seen in the larger venture capital environment, where funding continues to fall. But investment is still at years-low levels.
Abbott cuts jobs amid dwindling demand for COVID tests
The layoffs at Abbott’s manufacturing plant come after the COVID-19 public health emergency expired this month, and the company forecasts decreasing demand for the tests this year.
Providence narrowed losses as patient volumes increased
The Renton, Washington-based health system said inflation, labor shortages, delayed reimbursement from payers and supply chain problems are still affecting its bottom line, but its financial outlook is improving.
Pharma-backed report targets federal clinics for benefiting financially from 340B drug discounts
Those grantees on average are reimbursed almost four times more for 340B prescription drugs than what they pay, and make billions in 340B drug margin, according to the report, which was funded by Gilead Sciences.